- Conditions
- Type 2 Diabetes, Heart Failure
- Interventions
- Oral semaglutide, Sitagliptin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25,664 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Condition Directory
Heart Failure clinical trials
Directory of U.S. ClinicalTrials.gov public records for Heart Failure. Browse Heart Failure recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 1, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
283
Shown on this page
12
Current sort
Recently updated
Condition scope
Heart Failure
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Heart Failure studies are organized in the registry
Heart failure records routinely distinguish reduced versus preserved ejection fraction — the abbreviations HFrEF and HFpEF appear directly in titles and condition fields and are the cleanest way to split the portfolio. Device and monitoring studies form a substantial share alongside drug trials.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 13–24 of 283 matching trials for Heart Failure.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF
- Interventions
- Greater Splanchnic Nerve Ablation, Sham Control
- Device
- Lead sponsor
- Axon Therapies, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 17 more
- Conditions
- Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
- Interventions
- Maridebart cafraglutide, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 5,056 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 107 more
- Conditions
- Heart Failure, Diastolic
- Interventions
- Positive or negative pressure
- Diagnostic Test
- Lead sponsor
- Duke University
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Heart Failure, Acute Heart Failure
- Interventions
- Finerenone, Placebo
- Drug
- Lead sponsor
- Colorado Prevention Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 72 more
- Conditions
- Heart Failure
- Interventions
- Ziltivekimab, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,899 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 172
- States / cities
- Alexander City, Alabama • Fairhope, Alabama • Huntsville, Alabama + 141 more
- Conditions
- Pulmonary Hypertension Associated With HFpEF
- Interventions
- TNX-103
- Drug
- Lead sponsor
- Tenax Therapeutics, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 6 more
- Conditions
- Heart Failure Preserved Ejection Fraction, Resistant Hypertension
- Interventions
- Allopurinol
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Iron-deficiency, Heart Failure With Preserved Ejection Fraction
- Interventions
- Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric], Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFPEF)
- Interventions
- Weight loss SOC Treatment with second generation anti-diabetic medications
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Heart Failure, Systemic Inflammation
- Interventions
- Ziltivekimab, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 680 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 37
- States / cities
- Alexander City, Alabama • Fairhope, Alabama • Little Rock, Arkansas + 33 more
- Conditions
- Heart Failure, Heart Failure Preserved Ejection Fraction, Cardiovascular Diseases, Heart Diseases
- Interventions
- Tovinontrine (CRD-750), Placebo
- Drug
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 19 more
About this Heart Failure clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Heart Failure as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Heart Failure.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Heart Failure.